Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis -- Ignore unavailable to you. Want to Upgrade?

To: Robert Busse who wrote (1255)	11/20/1997 8:22:00 AM
From: Mike Relyea	Read Replies (4) \| Respond to of 1693

Bob, My take on the Trinity conference call ( techstocks.com ) is bullish for Quidel and so, so for Trinity: Why would Dr. Pronovost (sp ?) leave Quidel? Why would Trinity higher him? Mission completed!!! - Dr. Pronovost (and crew) succeeded!!! Quidel's got CLIA approved tests, and knows what it takes to get them. Does Quidel need Dr. Pronovost any more? Maybe not - remember, mission accomplished. Now, if I were Dr. Pronovost, I'd probably look for another mountain to conquer. This leads me to believe Trinity hasn't yet make it to the top. It appears Trinity's got a great one-sep test format, but it still needs some tweaking to be CLIA approved. According to the conference call, the tests are almost there, but no quite. Ya, well give me the bird in the hand. This probably gives Quidel an advantage. Trinity's "CLIA approved" one-steps look like they're at least a year away from FDA approval. In the mean time, Quidel's continuing to make a name for itself. The path to success takes a few big steps: first R&D, then FDA submission, then FDA approval, then MARKETING. Let's look at Trinity's one-steps, were Trinity says the 30 percent industry growth is. For Trinity's one-step CLIA approved tests: R&D - in progress; FDA submission - pending; FDA approvel - pending; distribution to POC locations - nowhere to be found. Quidel's a different story: R&D, FDA submission and approval, and distribution are all in place. Quidel's developing it's brand name, while Trinity's hiring Dr. Pronovost to get it past step one. I own some Trinity, but my big money's on Quidel. Even if Trinity gets approval for one-step CLIA approved tests, I'm confident there's enough of a market in the immerging POC one-step market to bring smiles to the faces of both Trinity's and Quidel's investors. Baring some blockbuster announcement, I think both Quidel and Trinity will have to post a few quarters of some solid earnings growth before their stock prices take off, and I think Quidel's now in a much better position to do this than Trinity. Mike